

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 19223

Title: Advanced Gastric cancer: current treatment landscape and future perspectives

Reviewer's code: 03016888

Reviewer's country: Japan

Science editor: Jing Yu

Date sent for review: 2015-05-08 09:38

Date reviewed: 2015-06-29 19:57

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

Dr. Antonia Digkila reviewed systemic therapy for gastric cancer comprehensively, and summarize chemotherapy, targeted therapy, and immune therapy as well. It can be easy to understand for all readers. Now, many clinical trials are on-going and many were already reported at ASCO, ESMO, and so on. We always effort to get information about the clinical trial. The reviewer would like to provide some results of pivotal studies to the authors, because some data are not updated. 1. The authors stated the results of JCOG9912 study in the "1st line treatment" section. The JCOG9912 study is a negative trial which did not show the superiority of irinotecan plus cisplatin to 5-FU alone. On the other hand, SPIRITS trial which is a phase III study comparing S-1 alone with S-1 plus cisplatin showed the superiority of doublet to single agent. If the authors would like to mention the superiority of doublet therapy, the SPIRITS trial is preferred. 2. The treatment schedule of SOX regimen is S-1 40 mg /m² bid for 14 days and oaliplatin 100 mg/m² d1 every 3 weeks. 3. In the "Targeting EGFR1 in advanced gastric cancer" section, nimotuzumab which is a EGFR inhibitor is under investigation by a phase III study in Japan and Korea (NCT01813253). Adding this trial is preferred. 4. In "Role of angiogenesis" section, a phase III study showed apatinib which is a VEGFR-2



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

TKI prolong OS compared with BSC in ASCO 2014. The inhibition of VEGFR-2 might be an important treatment strategy for advanced gastric cancer. 5. In "Future perspectives" section, the authors stated "Table 1". Where is Table 1? 6. The phase III study, RILOMET-1 was reported at ASCO 2015, and this study was did not meet primary endpoint. In addition, another phase III study including a novel agent, metmab (onartuzumab) showed no survival benefit of onartuzumab for gastric cancer in ASCO 2015. 7. Updated data of KEYNOTE-012 study was reported in ASCO 2015 by Dr. Bang. The median OS was 11.4 months.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 19223

Title: Advanced Gastric cancer: current treatment landscape and future perspectives

Reviewer's code: 00502797

Reviewer's country: Greece

Science editor: Jing Yu

Date sent for review: 2015-05-08 09:38

Date reviewed: 2015-06-30 21:10

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Points of criticism: 1. The manuscript needs minor linguistic improvement 2. The number of references is not high enough for a review regarding treatment modalities and future directions regarding gastric cancer 3. More details should be given on genetics of gastric cancer and new potent pathways that would lead to modern treatment strategies.